IntroductionChinese hamster ovary cells (CHO) are the expression system of choice in the bioproduction market for the manufacturing of bio‐therapeutic proteins. The first CHO cell lines were established by Puck in 1957, and since then many different lineages were established such as CHO‐S, CHO‐K1, CHOK1SV, DG44, and others. In general, CHO cells are robust, able to grow to high densities in suspension culture while maintaining high viability in large‐scale bioreactors, and can produce protein bio‐therapeutics in the 1–10 g/L range. Typically, stably transfected clones are generated to express bio‐pharmaceutically relevant proteins of interest. Once a cell line is developed, productivity and expression of a specific quality profile can be achieved through process optimization. The goal of such process development work is to maximize yield while maintaining critical quality attributes of the product. This is often achieved through optimization of culture medium, and production processes. Historically, mammalian cell culture medium and feed development has been based on iterative empirical approaches, which are both time consuming and costly. Although development efforts have improved by moving toward high‐throughput component screening in systems that are representative of large‐scale bioproduction processes, there continues to be a financial push to decrease time and effort associated with
Biotechnology Journal – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera